Nanobiotix Shares Drop 3% and Plunge 17% Over a Month Despite +700% in 2025

The stock loses ground and moves away from its short-term moving averages

Nanobiotix shares decline by 3.15% to €30.14, from a reference price of €31.12 the previous day. The stock is among the largest declines in the SBF 120, while the broader index remains nearly stable at 6,305.28 points. This movement extends the consolidation phase that started after the record high in mid-May, with a decline of 17.3% over the month. However, the annual performance remains spectacular at over 700%, and the price is still 31% above the MM200 (€22.97). In the short term, however, the configuration deteriorates: the price has fallen below the MM20 (€31.08, a gap of -3%) and more significantly below the MM50 (€32.51, a gap of -7.3%). The RSI at 48 remains neutral, indicating neither overbought nor oversold conditions, while the technical support at €28.28 is approaching.

Bearish pressure intensifies, short selling on the rise

According to statements reviewed, two funds now cumulatively hold 1.12% of the capital sold short, compared to no exposure a month earlier. This rapid increase reflects a rise in bearish pressure on the stock, though it has not yet reached a level of massive stress given the still modest extent of the total. The movement should be monitored over time rather than seen as an isolated signal of mistrust. Meanwhile, the internal context remains supportive on the clinical front: during the first quarter of 2026 publication (June 2), the biotech had strengthened its net cash position to €42.1 million and presented encouraging Phase 2 data for JNJ-1900 (NBTXR3) in inoperable lung cancer. The €28.28 support now becomes the technical marker to watch if the decline continues.